Title: Immunotherapy; a ground-breaking remedy for spinal cord injury with stumbling blocks: An overview
- PMID: 36778022
- PMCID: PMC9909832
- DOI: 10.3389/fphar.2023.1110008
Title: Immunotherapy; a ground-breaking remedy for spinal cord injury with stumbling blocks: An overview
Abstract
Spinal cord injury (SCI) is a debilitating disorder with no known standard and effective treatment. Despite its ability to exacerbate SCI sequel by accelerating auto-reactive immune cells, an immune response is also considered essential to the healing process. Therefore, immunotherapeutic strategies targeting spinal cord injuries may benefit from the dual nature of immune responses. An increasing body of research suggests that immunization against myelin inhibitors can promote axon remyelination after SCI. However, despite advancements in our understanding of neuroimmune responses, immunoregulation-based therapeutic strategies have yet to receive widespread acceptance. Therefore, it is a prerequisite to enhance the understanding of immune regulation to ensure the safety and efficacy of immunotherapeutic treatments. The objective of the present study was to provide an overview of previous studies regarding the advantages and limitations of immunotherapeutic strategies for functional recovery after spinal cord injury, especially in light of limiting factors related to DNA and cell-based vaccination strategies by providing a novel prospect to lay the foundation for future studies that will help devise a safe and effective treatment for spinal cord injury.
Keywords: DNA vaccination; immunoregulation; immunotherapy; myelin associated inhibitors; spinal cord injury.
Copyright © 2023 Saeed.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Immunotherapy strategies for spinal cord injury.Curr Pharm Biotechnol. 2015;16(6):492-505. doi: 10.2174/138920101606150407112646. Curr Pharm Biotechnol. 2015. PMID: 25860061 Review.
-
Remyelination after spinal cord injury: is it a target for repair?Prog Neurobiol. 2014 Jun;117:54-72. doi: 10.1016/j.pneurobio.2014.02.006. Epub 2014 Feb 28. Prog Neurobiol. 2014. PMID: 24582777 Review.
-
From demyelination to remyelination: the road toward therapies for spinal cord injury.Glia. 2015 Jul;63(7):1101-25. doi: 10.1002/glia.22809. Epub 2015 Mar 2. Glia. 2015. PMID: 25731941 Review.
-
Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy.J Neurosci. 2002 Apr 1;22(7):2690-700. doi: 10.1523/JNEUROSCI.22-07-02690.2002. J Neurosci. 2002. PMID: 11923434 Free PMC article.
-
The role of timing in the treatment of spinal cord injury.Biomed Pharmacother. 2017 Aug;92:128-139. doi: 10.1016/j.biopha.2017.05.048. Epub 2017 May 20. Biomed Pharmacother. 2017. PMID: 28535416 Review.
Cited by
-
Enhanced axon outgrowth of spinal motor neurons in co-culturing with dorsal root ganglions antagonizes the growth inhibitory environment.Regen Ther. 2023 Dec 10;25:68-76. doi: 10.1016/j.reth.2023.11.013. eCollection 2024 Mar. Regen Ther. 2023. PMID: 38148872 Free PMC article.
-
Immunoregulation of Glia after spinal cord injury: a bibliometric analysis.Front Immunol. 2024 Jun 13;15:1402349. doi: 10.3389/fimmu.2024.1402349. eCollection 2024. Front Immunol. 2024. PMID: 38938572 Free PMC article.
-
Improving Efficiency of Direct Pro-Neural Reprogramming: Much-Needed Aid for Neuroregeneration in Spinal Cord Injury.Cells. 2023 Oct 20;12(20):2499. doi: 10.3390/cells12202499. Cells. 2023. PMID: 37887343 Free PMC article. Review.
References
-
- Abbas W. A., Ibrahim M. E., El-Naggar M., Abass W. A., Abdullah I. H., Awad B. I., et al. (2020). Recent advances in the regenerative approaches for traumatic spinal cord injury: Materials perspective. ACS Biomater. Sci. Eng. 146 (12), 6490–6509. - PubMed
Publication types
LinkOut - more resources
Full Text Sources